Omeicos Therapeutics Gmbh Is A Clinical Stage Biotechnology Company Based In Berlingermanyfounded In 2013The Company Is Dedicated To Developing Innovative Therapies For Cardiovascularinflammatoryand Mitochondrial Diseasesomeicos Utilizes Its Expertise In Omega 3 Fatty Acid Metabolism To Create Small Molecules That Activate Protective Pathways In Cells The Company S Lead Compoundomt 28Is Currently In Phase Ii Clinical Trials For Treating Atrial Fibrillation And Primary Mitochondrial Diseasesomt 28 Has Shown Promising Results In Improving Safety And Efficacyparticularly In Reducing Inflammatory Biomarkers And Addressing Mitochondrial Dysfunctionomeicos Is Also Exploring Therapeutic Applications In Ophthalmologytargeting Severe Eye Disorders Like Wet Age Related Macular Degenerationwith Preclinical Data Indicating Potential Benefits Comparable To Existing Treatments With A Strong Focus On Advancing Its Clinical Pipelineomeicos Has Secured Significant Financing To Support Its Development Activities And Operates With An Efficient Structure To Manage Its Projects Effectively
No conferences found for this company.
| Company Name | Omeicos Therapeutics Gmbh |
| Country |
Germany
|
| Address | N/A |
| Telephone | N/A |
| N/A |
